论文部分内容阅读
目的探讨联合检测Ca125、Ca72-4在鉴别诊断卵巢肿瘤中的应用价值。方法选择51例卵巢恶性、48例卵巢良性肿瘤患者(观察组)和112例健康妇女(对照组),采用电化学发光法测定血清中Ca125、Ca72-4等指标进行比较分析。结果卵巢恶性肿瘤患者血清Ca125、Ca72-4含量明显高于卵巢良性肿瘤及健康人群(P<0.01);联合检测的阳性率达90.2%。结论联合检测Ca125、Ca72-4对于鉴别诊断卵巢良恶性肿瘤以及提高卵巢恶性肿瘤的诊断率具有一定的应用价值。
Objective To explore the value of combined detection of Ca125 and Ca72-4 in the differential diagnosis of ovarian tumors. Methods 51 cases of malignant ovarian tumors, 48 cases of benign ovarian tumors (observation group) and 112 healthy women (control group) were selected. Electrochemical chemiluminescence was used to determine the serum Ca125, Ca72-4 and other indicators for comparative analysis. Results The serum levels of Ca125 and Ca72-4 in patients with ovarian cancer were significantly higher than those in benign ovarian tumors and healthy people (P <0.01). The positive rate of combined detection was 90.2%. Conclusions The combined detection of Ca125 and Ca72-4 has certain value in differential diagnosis of benign and malignant ovarian tumors and in the diagnosis of ovarian malignant tumors.